1 / 71

Management of Chemo-immunotherapy toxicities

Management of Chemo-immunotherapy toxicities. Characteristics of Cancer Cells –the problem to us all. Cell cycle acceleration with rapid division Immortality cell due to diminished apoptosis Altered cell-cell communication and disordered proliferation

reeves
Download Presentation

Management of Chemo-immunotherapy toxicities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of Chemo-immunotherapy toxicities

  2. Characteristics of Cancer Cells –the problem to us all • Cell cycle acceleration with rapid division • Immortality cell due to diminished apoptosis • Altered cell-cell communication and disordered proliferation • Invasiveness and metastasis threaten healthy organs and ultimately compromises the host

  3. Cancer Cells versus the best of men – left unchecked -- who is likely to win?

  4. Goal of Cancer Treatments • Curative • Palliative • Minimize toxicity • Improve quality of life • Scientifically garner lessons learned to improve future care

  5. Established Treatment Modalities • Surgery • Radiotherapy • Chemotherapy including stem cell transplant • Endocrine therapy • Immunotherapy • Biological therapy

  6. Chemo-immunotherapy Classes • Targeted therapies target moleculary defined target: Gleevec, gefitinib, sunitinib and bortezomib • Differentiating agents : retinoids, ATRA and bexarotene, arsenic trioxide • Hormone therapy in hormone driven cancers such as breast, prostate, and endometrial cancers • Immunotherapy can be active or passive or non-specific: rituximab, campath, IL-2, BCG, interferon • Immunomodulating drugs include thalidomide, lenalidomide, Provenge

  7. Anti-cancer drugs

  8. Alkylating agents directly damage DNA and not phase-specific • Antimetabolites –interrupt DNA and RNA and are S- phase cell cycle specific. • Anti-tumor antibiotics such as anthracyclines interfere with DNA replication enzymes • Not phase specific • Topoisomerase inhibitors -- interfere with topoisomerases & copying of DNA strands • Mitotic inhibitors -- plant alkaloids and interfere with mitosis • Mostly M- phase of the cell cycle

  9. CommonToxicities to many of these agents • Myelosuppression • Gastrointestinal – nausea/vomitting • Dermatology – Alopecia, hand-foot syndrome • Neurologic toxicity • Tumor lysis syndrome

  10. Case • Staff Seargent Jones is a 25 y/o female with metastatic colorectal cancer in the setting of family history of HNPCC • She started cycle 2 chemoimmunotherapy with 5-FU and cetuximab 2 days ago • She now presents to you as ER admitting resident with c/o nausea/vomitting and inability to keep food down • Exam: • VS: Bp 95/50 HR 110 Temp 98.5 • ill-appearing but no focal findings except mild cachexia and hyperpigmented palms, feet and lips • Hgb 8, wbc 3.6, plt 40, ALT 100, AST 79, Tbili 1.3 Bun 35 sCR 1.8 • You will now do what?

  11. Gastrointestinal Complication • TOXIC INJURY OF ORAL AND GASTROINTESTINAL MUCOSA • CLINICAL SYMPTOMS - stomatitis with ulceration and pain - abdominal pain, watery stools not related to infection, hemorrhagic stools • CONSEQUENCES - infections  mainly with opportunistic endogenous GI microflora - bleeding - perforation - worsening of general status due to poor nutrition

  12. NAUSEA AND VOMITING • PATOGENESIS • Not well understood • One hypthesis = chemotherapy causes 5HT release from enterochromafin cells of stomach and gut, activating its receptors and initiating depolarization of vagus nerve • Uncontrolled chemotherapy induced naseau/vomitting results in - difficulties with oral drugs administration and oral feeding - exacerbation of oral cavity, pharynx and esophagus mucosal injury - Suboptimal chemo treatment due to drug discontinuation

  13. Scope of the problem -- Chemotherapy Induced Nausea Vomitting (CINV) • Incidence of acute and delayed N&V prospectively studied in 298 adult patients receiving HEC or MEC for the first time from 14 oncology practices in six countries • Patients completed a 6-day diary including emetic episodes, nausea assessment, and antiemetic medication use • Result: • Overall incidence of acute nausea > 35% and acute emesis = 13% • Delayed nausea with HEC pt = 60% and emesis = 50% • Delayed nausea with MEC pt = 52% and emesis = 28% • Delayed symptoms appeared without acute symptoms after HEC (emesis, 38%; nausea, 33%) and MEC (emesis, 19%; nausea, 21%) • ** >75% of physicians and nurses underestimated the incidence of delayed CINV after both HEC and MEC Grunberg SM, Deuson RR, Mavros P, et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100 (10): 2261-8, 2004

  14. Classification schema • Acute • Begins 1-2 hrs after initiation, peaks at 4 hrs • Delayed • >24 hours after chemo • Anticipatory/hyperacute • Prior to chemotherapy as a conditioned reaction to prior episodes of emesis with treatment

  15. Patient-specific risk factors • Higher-risk groups • Young • Female • High pretreatment expectation of nausea • Poor n/v control with prior chemotherapy • High ETOH consumption = ? negative risk factor

  16. #1 risk factor is drug dependent • The type of chemotherapy delivered • Dose • schedule of administration • route • individual patient variables

  17. Chemo Emetogenic Potential • High (level 4) • >90% risk of emesis without treatment • Moderate (level 3) • 31-90% risk of emesis without treatment • Low (level 2) • 10-30% risk of emesis without treatment • Minimal (level 1) • <10% risk of emesis without treatment Kris MG, Hesketh PJ, Somerfield MR, et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24 (18): 2932-47, 2006

  18. Classes & examples of Anti-emetics • 5-HT3 Receptor Antagonists: Ondansetron, Granisetron ,Dolasetron, Palonosetron • Substance P Antagonists (NK-1 Receptor Antagonists • Corticosteroids • Benzodiazepines:  Lorazepam, Olanzapine • Phenothiazines: Prochlorperazine • 
Butyrophenones:  Droperidol and haloperidol • 
Dopamine 2 Antagonists: Metoclopramide 
 • Cannabis – don’t medically recommend to patients as a military physician



  19. 5-HT3 antagonists • Cornerstone of controlling acute nause/vomitting • Equally effective across older formulations • Few adverse effects – HA, constipation • Relatively convenient dosing • Lower efficacy for delayed type of nause/vomitting • Even the generic remain expensive • Palonosetron (Aloxi) • Longer half life -- 40 hours • Better against delayed n/v • Studies ongoing to determine whether or not it should be the 5-HT3 antagonist of choice

  20. Neurokinin-1 (NK-1) antagonists • Aprepitant (Emend) • Oral drug only  125 mg po day 1, 80 mg po day 2-3 • Resulted in significant n/v improvement compared to dexamethasone alone or dexamethasone with 5-HT3 antagonist • Adverse events: Hiccups, dyspepsia • Very expensive --three tabs = $322 • CYP 450 3A4 inducer

  21. Corticosteroids • Old drugs with unclear mechanism for controlling CINV • Best when used with other anti-emetics • Effective for acute and delayed CINV • Dexamethasone • 20 mg IV for highly emetogenic • 8-20 mg for less emetogenic • Continue PO daily or BID for 4 days • Methylprednisolone IV also used

  22. Other adjunctive antiemetic • Benzodiazepine  helpful in anticipatory n/v • Lorazepam used first line • Metoclopramide (Reglan) • Prochlorperazine (Compazine) • Dronabinol (Marinol) • Olanzapine (Zyprexa) • Has ODT formulation and may be helpful in sundowning inpatients with n/v

  23. Breakthrough & Refractory Emesis • Challenging to reverse when preventive agents fails • Ensure adequate hydration and consider admission • Check and correct electrolyte imbalances • Use IV route and scheduled doses • May lead to anticipatory nausea/vomiting with next cycle if uncontrolled • For refractory emesis • Supportive care, hydration, nutritional supplementation • Strongly consider cessation/alteration of chemotherapy regimen

  24. Think Outside the Box (TOB) • Could it be disease related • Brain mets • Bowel obstruction • Paraneoplastic effects (hypercalcemia, hyponatremia) • Radiation enteritis • Could it be new infection • Could other emetogenic meds like opioids be contributing?

  25. Case – Hospital day 2 • Staff Sergeant Jones is feeling better with schedule anti-emetics, rehydration and correction electrolytes discovered on additional labs • She reports 5 episodes of diarrhea overnight with increasing dysphagia • Exam show normal vital signs and oral lesions with new sores on bilateral lips • Labs: LFT 2.5 x ULN, wbc 2.2, ANC 800, hgb 7.8, plt 30, Bun 35 sCR 1.5 • What the clinical issues now and how would you proceed?

  26. Diarrhea • Major toxicity of several drugs used to treat gastrointestinal cancers such as 5-FU and irinotecan • Rule out infection before giving anti-motility agent – c-diff if at risk • Anti-Motility Drugs • Loperamide (Imodium) • Diphenoxylate (Lomotil) • Octreotide (Sandostatin) • Somatostatin analogue • Works to prolong GI transit time • Subcutaneous administration • Acute diarrheal reaction to irinotecan Atropine at time of treatment

  27. Mucositis (Mouth Sores) • More common with certain drugs • 5-fluorouracil (5-FU) • Methotrexate • Doxorubicin (Adriamycin) • Cyclophosphamide (Cytoxan)

  28. Mucositis • Prevention • Icing of the mouth during treatment • Treatment Options • Gel Clear • Magic Mouthwash • Viscous lidocaine • Narcotics • Maintain vigilance for both local viral and systemic infection

  29. HEPATOTOXICITY • Etiology – many drugs and infection • CONSEQUENCES are many including suboptimal drug delivery, bleeding due to poor synthetic funciton and long term liver compromise • SURVEILLANCE - serum bilirubin, AlAt, AspAt, GGTP, NH3, PT/PTT - Liver u/s and biopsy as needed • PREVENTION - Dose adjustment to current liver function - Monitor infection with hepatotropic viruses (HBV, HCV)

  30. RENAL TOXICITY • Classic nephrotoxic chemotherapy = platinum drugs (cisplatin, carboplatin, less so oxaliplatin) and methotrexate • PREVENTION - cisplatin – administration of magnesium sulphate, mannitol for diuresis induction and hyperhydratation - metotrexate – hyperhydratation, diuretics,urine alkalization - Avoid and discontinue concomittant nephrotoxin NSAIDS, IV contrast etc

  31. Case – Hospital day 4 • Nurse reports to you that Staff Sergeant Jones has fever of 100.5 with chills • You give verbal stat orders for labs and xray • Nurse raises concern that you should come to ward and evaluate patient as the team just left • Your exam demonstrates an ill appearing pt shivering in bed. She reports to you that she is fatigued & her feet and hand “feels funny”. Temp is reported with BP 95/50 and HR 120. Severe mucositis is present. Lung and heart otherwise nl. Left upper arm picc line site is erythematous without exudate. • She has no other vascular access • STAT labs show LFT 3 x ULN, wbc 1.1, ANC 400, hgb 5.8, plt 18, Bun 35 sCR 1.3 • How would you proceed?

  32. Case – Hospital day 4 • Clinical problems • Fatigue • Diarrhea • Neutropenic fever with unstable VS • Possible Catheter related line infection • Grade 3 Anemia and thrombocytopenia • Worsening mucositis – you’re dealing with this !! • Hepatic and renal dysfunction – you know this already !! • And what’s with the hyperpigmented feet and hand feeling funny?

  33. Fatigue: Multifactorial • Anemia • Erythropoietin (Procrit)/darbepoetin (Aranesp) • Depression • Selective serotonin reuptake inhibitor (SSRI) • Sleep Disturbance -- Sleep aid: zolpidem tartrate (Ambien), eszopiclone (Lunesta) • Psychostimulants -- Methylphenidate (Ritalin)

  34. Bone marrow suppression • Very common complication of chemotherapy • Has potential to cause mortality than any other complication • Leads to • Thromocytopenia – bleeding and more bleeding • Anemia – fatigue, cardiovascular and cerebrovascular events • Neutropenia – bacterial infection • Lymphopenia and hypogammaglobulinemia => risk of viral, fungal and protozoal infection

  35. Neutropenic Fever • Neutropenic fever is a medical emergency • Infectious mortality in chemotherapy patients was 75% before empiric antibiotic therapy became the standard of care • Similar mortality (70% ) seen with a delay in administration of empiric antibiotics in patients with neutropenic fever • The Infectious Disease Society of America (IDSA) guideline provides best of expert advice -- last updated 2010

  36. NEUTROPENIA FEVER

  37. Duration and extent of bone marrow depression depends on drug

  38. NEUTROPENIA

  39. CHANGING PARADIGMS • Shift from Gram-positive to Gram-negative pathogens • New Gram-positive and Gram-negative • Increasing importance of fungi, especially Candida sp in neutropenic patients • Increasing incidence of resistant pathogens (MRSA, VRE, Candida) • Availability of G-CSF and GM-CSF • Development of broad spectrum antimicrobials • Early use of empiric antimicrobial therapy • Improved infection control • Use of prophylactic antimicrobial therapy remain controversial and not adviced

  40. IDSA INITIAL ANTIBIOTIC CONSIDERATION • Only 23% of febrile neutropenic episodes are assocaited with bacteremia • Gram positive organism – 57% with 5% mortality • Gram negative organisms – 34% with 18% mortality • Polymicrobial –9% • The goal of initial empiric abx is to prevent serious mortality and morbidiy • Coverage of pseudomonas aeruginosa continues to drive initial antibiotic choices IDSA 2010 update accessed 1/3/12

  41. IDSA INITIAL ANTIBIOTIC THERAPY CONSIDERATION • Negative blood cultures does not preclude empiric antibiotics in febrile neutropenic patients • May have occult infection • No clinical trial have shown superiority of one single empiric regimen • Ultimate selection should be based on • Whether patient’s risk is low vs high • Localizing infectious signs or symptoms – pulmonary infiltrates or cellulitis • Epidemiologic trends of pathogens causing infections in neutropenic patients • Special attention to local and individual patient patterns of bacterial colonization and resistance IDSA 2010 update accessed 1/3/12

  42. IDSA INITIAL ANTIBIOTIC THERAPY CONSIDERATION • Drug allergies • Drug interactions • Organ dysfunction -- renal and liver IDSA 2010 update accessed 1/3/12

  43. Initial management of fever and neutropenia—IDSA 2010 update

  44. Initial management of fever and neutropenia—IDSA 2010 update

  45. IDSA INITIAL ANTIBIOTIC THERAPY CONSIDERATION IDSA 2010 update accessed 1/3/12

More Related